Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2021-02-12 4:16 pm Purchase |
2020-12-31 | 13G | Merus N.V. MRUS |
BIOTECHNOLOGY VALUE FUND L P | 5,805,571 19.960% |
815,000 (+16.33%) |
Filing History |
| 2021-02-12 4:15 pm Sale |
2020-12-31 | 13G | Kezar Life Sciences, Inc. KZR |
BIOTECHNOLOGY VALUE FUND L P | 0 0.000% |
-203,979 (Position Closed) |
Filing History |
| 2021-02-12 4:13 pm Sale |
2020-12-31 | 13G | Galmed Pharmaceuticals Ltd. GLMD |
BIOTECHNOLOGY VALUE FUND L P | 9,998 8.400% |
-182 (-1.79%) |
Filing History |
| 2021-02-12 4:11 pm Purchase |
2020-12-31 | 13G | Forte Biosciences, Inc. FBRX |
BIOTECHNOLOGY VALUE FUND L P | 53,770 9.990% |
10,171 (+23.33%) |
Filing History |
| 2021-02-12 4:09 pm Sale |
2020-12-31 | 13G | Corvus Pharmaceuticals, Inc. CRVS |
BIOTECHNOLOGY VALUE FUND L P | 2,898,797 9.990% |
-22,380 (-0.77%) |
Filing History |
| 2021-02-12 4:06 pm Purchase |
2020-12-31 | 13G | Cidara Therapeutics, Inc. CDTX |
BIOTECHNOLOGY VALUE FUND L P | 223,075 9.990% |
54,637 (+32.44%) |
Filing History |
| 2021-02-11 5:29 pm Sale |
2020-12-31 | 13G | MEI Pharma, Inc. MEIP |
BIOTECHNOLOGY VALUE FUND L P | 279,466 4.900% |
-64,856 (-18.84%) |
Filing History |
| 2021-02-11 5:27 pm Purchase |
2020-12-31 | 13G | CytomX Therapeutics, Inc. CTMX |
BIOTECHNOLOGY VALUE FUND L P | 5,576,471 12.100% |
950,060 (+20.54%) |
Filing History |
| 2021-02-11 5:25 pm Sale |
2020-12-31 | 13G | Calithera Biosciences, Inc. CALA |
BIOTECHNOLOGY VALUE FUND L P | 218,062 6.200% |
-136,470 (-38.49%) |
Filing History |
| 2021-02-11 5:23 pm Sale |
2020-12-31 | 13G | Molecular Templates, Inc. MTEM |
BIOTECHNOLOGY VALUE FUND L P | 184,075 5.500% |
-56,481 (-23.48%) |
Filing History |
| 2021-02-11 5:20 pm Purchase |
2020-12-31 | 13G | ESSA Pharma Inc. EPIX |
BIOTECHNOLOGY VALUE FUND L P | 3,705,289 11.000% |
1,064,724 (+40.32%) |
Filing History |
| 2021-02-11 5:18 pm Sale |
2020-12-31 | 13G | Forward Pharma A/S FWPAY |
BIOTECHNOLOGY VALUE FUND L P | 35,682 10.700% |
-13,643 (-27.66%) |
Filing History |
| 2021-02-11 5:16 pm Sale |
2020-12-31 | 13G | SpringWorks Therapeutics, Inc. SWTX |
BIOTECHNOLOGY VALUE FUND L P | 50 1.000% |
-3,079,105 (-100.00%) |
Filing History |
| 2021-02-11 5:14 pm Purchase |
2020-12-31 | 13G | GlycoMimetics, Inc. GLYC |
BIOTECHNOLOGY VALUE FUND L P | 9,544,262 19.960% |
2,182,461 (+29.65%) |
Filing History |
| 2021-02-11 5:12 pm Sale |
2020-12-31 | 13G | Replimune Group, Inc. REPL |
BIOTECHNOLOGY VALUE FUND L P | 0 0.000% |
-2,309,109 (Position Closed) |
Filing History |
| 2021-02-11 5:10 pm Sale |
2020-12-31 | 13G | Surface Oncology, Inc. SURF |
BIOTECHNOLOGY VALUE FUND L P | 0 0.000% |
-2,125,650 (Position Closed) |
Filing History |
| 2021-02-11 5:08 pm Sale |
2020-12-31 | 13G | Mersana Therapeutics, Inc. MRSN |
BIOTECHNOLOGY VALUE FUND L P | 0 0.000% |
-3,755,553 (Position Closed) |
Filing History |
| 2021-02-11 5:06 pm Purchase |
2020-12-31 | 13G | IDEAYA Biosciences, Inc. IDYA |
BIOTECHNOLOGY VALUE FUND L P | 3,226,769 11.100% |
2,597 (+0.08%) |
Filing History |
| 2021-02-11 4:59 pm Sale |
2020-12-31 | 13G | Kura Oncology, Inc. KURA |
BIOTECHNOLOGY VALUE FUND L P | 1,245,912 1.900% |
-1,188,784 (-48.83%) |
Filing History |
| 2021-02-11 4:52 pm Purchase |
2020-12-31 | 13G | Cogent Biosciences, Inc. COGT |
BIOTECHNOLOGY VALUE FUND L P | 3,114,250 4.700% |
3,114,250 (New Position) |
Filing History |